期刊文献+

卡维地洛治疗慢性充血性心力衰竭的疗效观察

下载PDF
导出
摘要 目的探讨应用卡维地洛治疗慢性心力衰竭(CHF)的效果。方法将90例心力衰竭患者随机分为卡维地洛治疗组和对照组各45例(NYHA分级Ⅱ~Ⅳ级)。对照组使用洋地黄、利尿剂、血管紧张素转换酶抑制剂、硝酸酯类等药物治疗;卡维地洛组在常规治疗的基础上,加用卡维地洛2.5 mg,2次/d,如能耐受,每隔2周将剂量加倍,直至最大耐受量(预定目标剂量为40 mg/d)。疗程6个月。观察治疗前、后不同时间左室射血分数(LVEF)、左室舒张末期内径(LVEDD)及心功能变化。结果治疗6个月后,卡维地洛组和对照组的NYHA分级、LVEF、LVEDD均较治疗前有显著性变化(P〈0.01,P〈0.05);但卡维地洛组比对照组变化更明显(P〈0.05)。结论在常规心力衰竭基础上加用卡维地洛能更加有效地改善CHF的心功能。
作者 胡京光
出处 《中原医刊》 2007年第18期23-24,共2页 Central Plains Medical Journal
  • 相关文献

参考文献8

  • 1慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2414
  • 2Remme W J , Riegger G , Hilldebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE - inhibitor in mild heart failure and left ventficular systolic dysfunction. The catvedilol and ACE - inhibitor remodeling mild heart failure evaluation trial(CARMEN). Cardiovasc Drugs Ther,2004,18( 1 ) :57 -66.
  • 3Poole - wilson PA, Swedberg K. Clelan JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial ( COMET ) : randomised controlled trial. Lancet,2003,362:7 -13.
  • 4杨田,沈萍,赵仙先.卡维地洛药理作用的研究进展[J].心血管病学进展,2003,24(2):110-113. 被引量:50
  • 5程日方.心力衰竭的治疗进展[J].中华中西医杂志,2003,4(10):650-650.
  • 6Stoschitzky K, Koshucharova G, Zweiker R, et al. Differing beta - blocking effects of carvedilol and metoprolol. Heart Failure, 2001,3 ( 3 ) : 343 - 349.
  • 7Cleland JGF, Swedberg K, Poole - wilson PA. Successes and failures of curent treatment of heart failure. Lancet, 1998,352 (Suppl) :19.
  • 8Seiman OI, Murin J, Ghanem WM. Beta - blockers in heart failure. Bratisl Lek Listy,2001,102:322 - 337.

二级参考文献25

  • 1[11]Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228 [J]. Biochem Pharmacol ,2001,61 (2): 155-164.
  • 2[12]Noguchi N, Nishino K,Niki E. Antioxidant action of the antihypertensive drug,carvedilol, against lipid peroxidation [J]. Biochem Pharmacol, 2000, 59 ( 9 ):1069-1076.
  • 3[13]Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis :protective role of carvedilol [J]. J Am Coll Cardilo,2001 ,36( 7 ) :2081-2089.
  • 4[14]Romeo F,LiM D,Shi M ,et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells:modulation of Fas/Fsa ligand and caspase-3 pathway [ J ]. Cardiovasc Res, 2000,45 ( 3 ) :788-794.
  • 5[15]Cao F,Chen J,Lopez BL,et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model [ J ]. Eur J Pharmacol,2000,406( 1 ) :109-116.
  • 6[16]Wei S.Chow LT,Sanderson JE,et al. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction[J]. J Am Coll Cardiol.2000,36( 1 ) :276-281.
  • 7[17]Ohta Y, Watanabe K, Nakazawa M,et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart[ J ]. J Cardiovasc Pharmacol,2000,36 ( suppl 2 ) 19-23.
  • 8[18]Savitz SI, Erhardt JA, Anhtony JV, et al. The novel β-bolcker, carvedilol, provides neuroprotection in transient focal stroke[J]. J Cereb Blood Flow Metab,2000,20(8) :1197-1204.
  • 9[19]Karle CA, Kreye VA,Thomas D, et al. Antarrhythmic drug carvedilol inhibits HERG potassium channels [ J ]. Cardiovasc Res,2001,49 ( 2 ): 361-370.
  • 10[20]Takusagawa M, Komori S, Matsumura K, et al. The inhibitory effects of carvedilol against arhytmias induced by coronary by coronary reperfusion in aneothetized rats [J]. J Cardiovasc Pharmacol Ther, 2000, 5 ( 2 ): 105 - 112.

共引文献2461

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部